YALE COMPREHENSIVE CANCER CENTER

耶鲁大学综合癌症中心

• 批准号: 8102613
• 负责人: Thomas James Lynch
• 金额: $ 9.79万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-07-01 至 2012-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8102613
• 关键词: Antineoplastic Agents; Biological; Budgets; Cancer Center Support Grant; Clinical; Clinical Investigator; Clinical Research; Clinical Sciences; Clinical Trials; Comprehensive Cancer Center; Consultations; Development; Direct Costs; Disorder by Site; Faculty; Funding; Gene Expression Regulation; Guidelines; Laboratories; Malignant Neoplasms; Medical Oncology; Modality; Molecular Diagnosis; Peer Review; Protocols documentation; Radiation therapy; Receptor Protein-Tyrosine Kinases; Recruitment Activity; Research; Research Personnel; Research Project Grants; Research Support; Review Committee; Schools; Science; Scientist; Services; Signal Transduction; Stress; Structure; Translations; Yale Cancer Center; base; cancer therapy; cost; design; functional genomics; inhibitor/antagonist; member; programs; small molecule

DESCRIPTION (provided by applicant): The Yale Cancer Center (YCC) was designated as an NCI Comprehensive Cancer Center in 1974. YCC has elected to profoundly alter its structure to better facilitate clinical translation of its abundant scientific strengths. A particularly important component, taken in consultation with the NCI, was relocation of operational control of Medical Oncology to YCC, to augment Center influence over the Clinical Trials Program. An administrative 3-year extension from the NCI enabled these changes. The new Director, Richard Edelson, an accomplished translational scientist, has led the Center since these pivotal changes were initiated in 2003. Over $68 million of institutional support permitted YCC to enhance facilities and recruit 60 external faculty members, including leaders of 5 of the 8 Research Programs, 6 of the 11 interdisciplinary cancer disease site teams and both the Clinical Research Services Core and Protocol Review Committee. Strategic scientific recruitments include Joseph Schlesinger (pioneer in the design of inhibitors of receptor tyrosine kinases and now Co-Leader of the Signal Transduction Program) and Jeffrey Sklar (a leading innovator in molecular diagnosis of cancer and now Co-Leader of the Gene Regulation and Functional Genomics Program). Preserving continuity by reappointing the Deputy Director, the Director appointed new Associate Directors of Basic and Clinical Sciences. All Research Programs now thematically stress mechanistic themes, and the Clinical Division has been organized around the three main cancer treatment modalities (small molecules/anticancer agents, radiation therapy, and biological/ immunological agents), rather than being confined to single disease sites. Due to these collective YCC structural and functional changes, the number of investigator initiated clinical trials, based on YCC science, have dramatically increased. Construction has begun on a $460M new Clinical Cancer Tower, proximal to the YCC scientific laboratories. The 210 YCC members come from 27 Yale Departments and 4 Schools. Since the last CCSG submission, total peer-reviewed, annual direct costs of cancer-relevant research support increased by 42%, from $43 million to $62 million, inclusive of $15.3 million from the NCI. Integration of the new scientific and clinical investigators has permitted the YCC to target 8 sets of grouped research projects for focused development. Last approved in 1998, YCC continues to satisfy guidelines for Comprehensiveness. Based on the NCI total cost funding base of $25.6 million, YCC is requesting a budget of $3.8 million in total costs.

描述（由申请人提供）：耶鲁大学癌症中心（YCC）于1974年被指定为NCI综合癌症中心。YCC选择深刻改变其结构，以更好地促进其丰富的科学优势的临床转化。与NCI协商后，一个特别重要的组成部分是将肿瘤内科的运营控制转移到YCC，以增强中心对临床试验项目的影响力。NCI的3年行政延期使这些变化成为可能。新主任理查德·埃德尔森是一位有成就的翻译科学家，自2003年启动这些关键变革以来一直领导着中心。超过6800万美元的机构支持使YCC能够加强设施并招募60名外部教师，包括8个研究项目中的5个，11个跨学科癌症疾病网站团队中的6个以及临床研究服务核心和方案审查委员会的领导者。战略科学招聘包括约瑟夫·施莱辛格（受体酪氨酸激酶抑制剂设计的先驱，现在是信号转导计划的共同负责人）和杰弗里·斯克拉（癌症分子诊断的领先创新者，现在是基因调控和功能基因组学计划的共同负责人）。为了保持连续性，重新任命了副主任，主任任命了新的基础和临床科学副主任。所有的研究项目现在都在主题上强调机械主题，临床部门围绕三种主要的癌症治疗方式（小分子/抗癌剂，放射治疗和生物/免疫剂）进行组织，而不是局限于单一的疾病部位。由于这些集体YCC结构和功能的变化，研究人员发起的基于YCC科学的临床试验的数量急剧增加。一座耗资4.6亿美元的新临床癌症塔已经开始建设，该塔靠近YCC科学实验室。YCC的210名成员来自耶鲁大学的27个系和4个学院。自上一次CCSG提交以来，癌症相关研究支持的年度直接费用总额增加了42%，从4300万美元增加到6200万美元，其中包括来自NCI的1530万美元。新的科学和临床研究人员的整合使YCC能够针对8组分组研究项目进行重点开发。上一次批准是在1998年，YCC继续满足全面性的指导方针。根据NCI总成本资金基础2 560万美元，YCC要求总成本预算为380万美元。